STOCKHOLM, Feb. 19, 2026 /PRNewswire/ --SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced that Nevisense (EIS) is ...
STOCKHOLM, April 27, 2026 /PRNewswire/ -- SciBase hereby announces that the Annual report for 2025 is available at the Company's website www.scibase.com. A pdf-version of the annual report is enclosed ...
STOCKHOLM, May 18, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced the presentation of a new ...
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care ...
STOCKHOLM, May 28, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a ...
STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue of shares ...
Net sales were TSEK 14,278 (8,856), +61%, cleared for currency effects +80%. The loss after tax was TSEK 24,490 (20,682). The loss per share was SEK 0.03 (0.07). The cash flow from current operations ...
STOCKHOLM--(BUSINESS WIRE)--SciBase, a Swedish medtech company that develops and markets a new method for early detection of malignant melanoma, has received approval from the United States Patent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results